Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Doxorubicin +/- Bleomycin and Vincristine in AIDS-KS
NCT00001059Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegylated liposomal doxorubicin in Kaposi sarcoma (KS) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Safety and Adverse Events and Efficacy. Status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT00001059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001059.